Interestingly, in dLN, the frequency of both CD8+ and CD4+ T cells were significantly decreased in (OT-II-Th9 + LB-100) group as compared to OT-II-Th9 group (Fig. 6d) indicating that Th9 cells treated with LB-100 suppressed the effector populations, especially CD8+ T cells, that are essential for regressing tumor growth. The gene discussed is CD8A; the disease is neoplasm.